Drugs / RSV F vaccine
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02296463 | Nov 2014 → Sep 2015 | respiratory syncytial virus infectious disease | Novavax | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT02593071 | Oct 2015 → Nov 2016 | respiratory syncytial virus infectious disease | Novavax | Completed | No outcome recorded |
| Phase 2 | NCT02266628 | Oct 2014 → Mar 2016 | respiratory syncytial virus infectious disease | Novavax | Completed | No outcome recorded |
| Phase 2 | NCT02247726 | Sep 2014 → Jul 2016 | respiratory syncytial virus infectious disease | Novavax | Completed | No outcome recorded |
| Phase 2 | NCT01704365 | Oct 2012 → Apr 2013 | respiratory syncytial virus infectious disease | Novavax | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02608502 | Nov 2015 → Dec 2016 | respiratory syncytial virus infectious disease | Novavax | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 2 | NCT03026348 Comparator | Jan → Apr 2017 | respiratory syncytial virus infectious disease | Novavax | Completed | No outcome recorded |
| Phase 3 | NCT02624947 Comparator | Dec 2015 → Dec 2018 | respiratory syncytial virus infectious disease | Novavax | Completed | No outcome recorded |
| — | NCT07460154 Comparator | Mar 2026 → Mar 2029 expected | chronic obstructive pulmonary disease | Northumbria Healthcare NHS Foundation Trust | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RSV F vaccine | “A recombinant RSV fusion protein nanoparticle vaccine (RSV F vaccine) candidate for maternal immunization was tested for safety and immunogenicity in women of childbearing age.” PMID 26259809 ↗ Aug 2015 |
| Known as | RSV fusion (F) protein nanoparticle vaccine | “Healthy pregnant women, at 28 weeks 0 days through 36 weeks 0 days of gestation, with an expected delivery date near the start of the RSV season, were randomly assigned in an...” PMID 32726529 ↗ Jul 2020 |
| Modality | Vaccine | “A recombinant RSV fusion protein nanoparticle vaccine (RSV F vaccine) candidate for maternal immunization was tested for safety and immunogenicity in women of childbearing age.” PMID 26259809 ↗ Aug 2015 |
| Route | Intramuscular | “0.5mL IM Injection” NCT01704365 ↗ |